Exchange: NYSE·Updated 12:27 PM EDT
BMY logo

BMYBristol-Myers Squibb Co.

$62.84
$0.75
(1.21%)
Today
EarningsJul 30
Mkt Cap$126.79B
Vol3.41M
News
all
press releases
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q2 Earnings
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks
More News
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $61.4, denoting a +1.05% move from the preceding trading day.
Zacks
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
Zacks
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
Zacks
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.
Zacks
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
Bristol Myers Squibb (NYSE: BMY, BMS), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned NVIDIA infrastructure in life...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.